Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Distinct immunogenomic features of cancers arising in solid organ transplant recipients.

Shyfuddin Ahmed, Christopher Blosser, Tolulope Tosin Adeyelu et al. Jun 01, 2026 pp. 10587-10587 10.1200/jco.2026.44.16_suppl.10587

10587 Background: Solid organ transplantation recipients (SOTRs) are at increased risk of cancer due to long-term immunosu...

Post-transplant outcomes stratified by induction therapy in patients with AML undergoing allogeneic transplantation.

Nicole Lisek, Yanal Mufeed Alnimer, Chandra Kakarala et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18572

e18572 Background: Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative option for patients...

From pathophysiology to prognosis: An oncology curriculum for interdisciplinary palliative care specialists.

Sinthana Ramsey, Vasilii Bushunow, Roby Antony Thomas et al. Jun 01, 2026 pp. 9026-9026 10.1200/jco.2026.44.16_suppl.9026

9026 Background: Integrating specialty palliative care (SPC) improves outcomes for patients with advanced cancer, yet effe...

CXCR2 expression in lung neuroendocrine neoplasms.

Huihua Li, Victor L. Roggli, Elizabeth N. Pavlisko Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20143

e20143 Background: The incidence of lung neuroendocrine neoplasms (NENs), which account for 1%-3% of all lung malignancies...

Factors associated with treatment response and survival outcomes in plasmablastic lymphoma: A retrospective study in a predominantly Hispanic population.

Hien Lau, Shirley Ye, Zaw Win Myint Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19099

e19099 Background: Plasmablastic lymphoma (PBL) is a rare, aggressive NHL with historically poor outcomes and a median ove...

Healthcare utilization and end-of-life care in pancreatic cancer: A single-institution cohort study.

Muhammad Areeb Ashfaq, Muhammad Dawood Amir Sheikh, Ahmed Abdalla Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23206

e23206 Background: Pancreatic cancer carries high symptom burden and frequent acute care use, yet real-world utilization a...

Clinical outcomes and cumulative cost of preventive surveillance versus treatment in Li–Fraumeni syndrome: Results from the European PREVENTABLE project.

Marion Rolain, Jean Christophe Thery, Ricardo Amorim et al. Jun 01, 2026 pp. 10553-10553 10.1200/jco.2026.44.16_suppl.10553

10553 Background: Li-Fraumeni syndrome (LFS), caused by TP53 pathogenic variants,...

A randomized phase II clinical trial of a fasting-mimic diet prior to chemotherapy to evaluate the impact on toxicity and efficacy.

Mahshid Shelechi, Denice Tsao-Wei, Jacek K. Pinski et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12522

e12522 Background: Fasting may help reduce the toxicity of certain chemotherapy drugs but a low calorie, low protein fasti...

Phase 1A/B study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab, in patients with advanced solid tumor malignancies.

Harriet M. Kluger, Alain Patrick Algazi, Rama Balaraman et al. Jun 01, 2026 pp. 2616-2616 10.1200/jco.2026.44.16_suppl.2616

2616 Background: High-dose IL-2 demonstrates modest activity in melanoma and RCC but its use is limited by severe toxicity...

A non-invasive methylation-based NGS assay for sensitive detection of pancreatic cancer.

Gang Jin, Shiwei Guo, Xiaohan Shi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16452

e16452 Background: Non-invasive tools with high sensitivity to distinguish pancreatic cancer from benign pancreatic lesion...

Phase II study of bevacizumab plus trifluridine/tipiracil and irinotecan as second-line therapy for RAS wild-type metastatic colorectal cancer.

Wenju Chen, Jiayu Niu, Shusheng Wu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15578

e15578 Background: Patients with RAS wild-type (RASwt) metastatic colorectal cancer (mCRC) progressing on first-line fluor...

Effects of external beam radiation therapy and androgen deprivation therapy on physical activity of men with non-metastatic prostate cancer.

Justin J. Zhao, Stephen G. Gonsalves, Alex Ross et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17028

e17028 Background: Physical activity (PA) has been shown to have a profound positive impact on the quality of life of peop...

Efficacy and safety of cetuximab-irinotecan rechallenge versus regorafenib in <i>RAS</i> wild-type metastatic colorectal cancer.

Hao Chen, Tao Jiang, Han Wang et al. Jun 01, 2026 pp. 3537-3537 10.1200/jco.2026.44.16_suppl.3537

3537 Background: Anti-epidermal growth factor receptor (EGFR) antibodies are widely used in the treatment of RAS wild-type...

A phase 1/2a, multicenter, first-in-human, open-label clinical trial evaluating MDX2004 monotherapy in patients with advanced tumors.

Jordan Ellis Cohen, Udit Nindra, Ruth Perets et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps2686

TPS2686 Background: MDX2004 is a trispecific antibody–fusion protein developed as an immunotherapy for advanced cancers. I...

The weight of each node: Modeling and quantifying breast cancer lymphedema risk.

Leonardo Kozian, Dylan Brokaw, Austin D. Williams et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12750

e12750 Background: Lymphedema (LE) is a common morbidity following breast cancer surgery, affecting quality of life. While...

Income inequality and cervical cancer: A comparative analysis of demographics and healthcare burden of women in the lowest and highest income quartiles.

Dhruvi Dipakkumar Pathak, Aishwarya Ramesh, Kesha Pathak et al. Jun 01, 2026 pp. 5521-5521 10.1200/jco.2026.44.16_suppl.5521

5521 Background: Cervical cancer disproportionately affects women of lower socioeconomic status, yet comprehensive data co...

A phase 2 trial of IO102-IO103 and nivolumab-relatlimab in previously untreated, unresectable melanoma.

James William Smithy, Hannah L. Kalvin, Jaykumar Ranchodbhai Thumar et al. Jun 01, 2026 pp. 9519-9519 10.1200/jco.2026.44.16_suppl.9519

9519 Background: IO102-IO103 is an investigational cancer vaccine that targets both tumor and immune-suppressive cells in...

Integrating a small extracellular vesicle protein–based ovarian cancer score with O-RADS Ultrasound to improve preoperative risk stratification of adnexal masses.

Qunxian Rao, Na Di, Yiru He et al. Jun 01, 2026 pp. 5555-5555 10.1200/jco.2026.44.16_suppl.5555

5555 Background: Accurate preoperative differentiation of adnexal masses remains a major clinical challenge. Although the...

Neighborhood social vulnerability and clinical trial enrollment in colon cancer: Does age matter?

Shannon S. Yoo, Hye Rim Jang, Ernie Shippey et al. Jun 01, 2026 pp. 1533-1533 10.1200/jco.2026.44.16_suppl.1533

1533 Background: Colorectal cancer is now the leading cause of cancer-related death in people under 50, and young adults l...

RINGSIDE: A phase 3 randomized, placebo-controlled trial of varegacestat for treatment of progressing desmoid tumors.

Mrinal M. Gounder, Piotr Rutkowski, Robin L. Jones et al. Jun 01, 2026 pp. 11506-11506 10.1200/jco.2026.44.16_suppl.11506

11506 Background: Desmoid tumors (DT) are rare, locally aggressive tumors with few effective treatments. Varegacestat (VAR...

Racial and ethnic differences in cardiovascular disease prevention and treatment amongst breast cancer survivors.

Adewumi T. Omoniyi, David Tofovic, Destiny Burnett Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23331

e23331 Background: Breast cancer is the second leading cause of cancer death among women in the U.S., and heart disease re...

Endometrial cancer risk management in patients with Lynch syndrome at a tertiary community cancer center.

Marianne E. Dubard-Gault, Sarah Hawley, Terry Gilbertson et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22539

e22539 Background: Lynch syndrome (LS) is a genetic predisposition associated with germline alterations in the DNA mismatc...

Iparomlimab and tuvonralimab (PD-1/CTLA-4 bifunctional antibody) monotherapy or combination therapy in patients with advanced solid tumors treated.

Jie Liu, Lin Wei, Jie Li et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23358

e23358 Background: Patients with advanced solid tumors that progress after first-line treatment, particularly after PD-(L)...

Geographic clustering of renal cell carcinoma in West Virginia counties with historical perfluorooctanoic acid (PFOA) exposure.

Hiba Khan, Sanjana Nethagani, Danielle DeCicco et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16525

e16525 Background: Perfluorooctanoic acid (PFOA), a persistent per- and polyfluoroalkyl substance (PFAS), has contaminated...

Gene and isoform transcriptomics to uncover distinct immune and signaling programs across sarcoma subtypes.

Tom Wei-Wu Chen, Chia-Lang Hsu, Zhong Wee Poh et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23538

e23538 Background: Sarcomas are heterogeneous malignancies arising from diverse mesenchymal lineages. While transcriptomic...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page